Diabetes:二甲双胍或可用于糖尿病并发视网膜病变者

2012-01-01 MedSci MedSci原创

近日,上海交通大学附属第一人民医院的研究人员针对糖尿病微血管和大血管并发症可发生细胞代谢记忆,但其基本机制尚不清楚这一问题展开研究。研究重点关注于上述现象中sirtuin1(SIRT1)和二甲双胍的作用。相关论文将发表在2012年1月的Diabetes上。 该研究证实了二甲双胍可抑制糖尿病视网膜的高血糖应激“记忆”,这表明SIRT1可能是治疗细胞代谢记忆的一个潜在治疗靶点,使用二甲双胍可能会

近日,上海交通大学附属第一人民医院的研究人员针对糖尿病微血管和大血管并发症可发生细胞代谢记忆,但其基本机制尚不清楚这一问题展开研究。研究重点关注于上述现象中sirtuin1(SIRT1)和二甲双胍的作用。相关论文将发表在2012年1月的Diabetes上。

该研究证实了二甲双胍可抑制糖尿病视网膜的高血糖应激“记忆”,这表明SIRT1可能是治疗细胞代谢记忆的一个潜在治疗靶点,使用二甲双胍可能会使糖尿病并发视网膜病变患者带来新的希望。

该研究针对血糖恢复正常后再次出现高血糖可诱发牛视网膜毛细血管内皮细胞(BRECs)和糖尿病小鼠视网膜中的炎症基因,核因子-κB(NF -κB)和凋亡基因Bax进行研究。BRECs小分子干扰RNA介导的SIRT1抑制提高了BRECs高血糖应激的敏感性,聚(ADP -核糖)聚合酶(PARP)通过上调肝激酶B1/AMP-活化的蛋白激酶(LKB1/AMPK)引起线粒体活性氧介导的3 - 磷酸甘油醛脱氢酶升高,而二甲双胍引起的SIRT1过度表达或激活会抑制这种升高,最终抑制NF -κB和Bax表达。此外,研究人员发现,高血糖可导致PARP激活,这反过来又可能下调SIRT1。(生物谷Bioon.com)

拓展阅读:

MARCH研究首项头对头比较阿卡波糖和二甲双胍降糖疗效研究

二甲双胍抗肿瘤作用之辩

Sirtuin 1-Mediated Cellular Metabolic Memory of High Glucose Via the LKB1/AMPK/ROS Pathway and Therapeutic Effects of Metformin.

Zheng Z, Chen H, Li J, Li T, Zheng B, Zheng Y, Jin H, He Y, Gu Q, Xu X.

Cellular metabolic memory occurs in diabetic microvascular and macrovascular complications, but the underlying mechanisms remain unclear. Here, we investigate the role of sirtuin 1 (SIRT1) and metformin in this phenomenon. In bovine retinal capillary endothelial cells (BRECs) and retinas of diabetic rats, the inflammatory gene, nuclear factor-κB (NF-κB), and the proapoptotic gene, Bax, induced by hyperglycemia, remained elevated after returning to normoglycemia. BRECs with small interfering RNA-mediated SIRT1 knockdown had increased sensitivity to hyperglycemia stress, whereas SIRT1 overexpression or activation by metformin inhibited the increase of mitochondrial reactive oxygen species-mediated glyceraldehyde-3-phosphate dehydrogenase by poly (ADP-ribose) polymerase (PARP) activity through the upregulation of liver kinase B1/AMP-activated protein kinase (LKB1/AMPK), ultimately suppressing NF-κB and Bax expression. Furthermore, we showed that hyperglycemia led to PARP activation, which in turn may have downregulated SIRT1. Of importance, this study also demonstrated that metformin suppressed the "memory" of hyperglycemia stress in the diabetic retinas, which may be involved in the SIRT1/LKB1/AMPK pathway. Our data suggest that SIRT1 is a potential therapeutic target for the treatment of the cellular metabolic memory, and the use of metformin specifically for such therapy may be a new avenue of investigation in the diabetes field.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759106, encodeId=0a6a1e5910623, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 17 23:21:00 CST 2012, time=2012-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757526, encodeId=394d1e575265e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 24 15:21:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636466, encodeId=34f416364665d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:21:00 CST 2012, time=2012-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900919, encodeId=6090190091946, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 02 17:21:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269763, encodeId=dc6b1269e6303, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413850, encodeId=326b141385080, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759106, encodeId=0a6a1e5910623, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 17 23:21:00 CST 2012, time=2012-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757526, encodeId=394d1e575265e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 24 15:21:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636466, encodeId=34f416364665d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:21:00 CST 2012, time=2012-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900919, encodeId=6090190091946, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 02 17:21:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269763, encodeId=dc6b1269e6303, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413850, encodeId=326b141385080, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=)]
    2012-07-24 丁鹏鹏
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759106, encodeId=0a6a1e5910623, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 17 23:21:00 CST 2012, time=2012-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757526, encodeId=394d1e575265e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 24 15:21:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636466, encodeId=34f416364665d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:21:00 CST 2012, time=2012-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900919, encodeId=6090190091946, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 02 17:21:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269763, encodeId=dc6b1269e6303, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413850, encodeId=326b141385080, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759106, encodeId=0a6a1e5910623, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 17 23:21:00 CST 2012, time=2012-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757526, encodeId=394d1e575265e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 24 15:21:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636466, encodeId=34f416364665d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:21:00 CST 2012, time=2012-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900919, encodeId=6090190091946, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 02 17:21:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269763, encodeId=dc6b1269e6303, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413850, encodeId=326b141385080, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1759106, encodeId=0a6a1e5910623, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 17 23:21:00 CST 2012, time=2012-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757526, encodeId=394d1e575265e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 24 15:21:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636466, encodeId=34f416364665d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:21:00 CST 2012, time=2012-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900919, encodeId=6090190091946, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 02 17:21:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269763, encodeId=dc6b1269e6303, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413850, encodeId=326b141385080, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=)]
    2012-01-02 zutt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1759106, encodeId=0a6a1e5910623, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 17 23:21:00 CST 2012, time=2012-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757526, encodeId=394d1e575265e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 24 15:21:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636466, encodeId=34f416364665d, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Mar 16 11:21:00 CST 2012, time=2012-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900919, encodeId=6090190091946, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Thu Aug 02 17:21:00 CST 2012, time=2012-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269763, encodeId=dc6b1269e6303, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413850, encodeId=326b141385080, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Mon Jan 02 15:21:00 CST 2012, time=2012-01-02, status=1, ipAttribution=)]

相关资讯

MARCH研究首项头对头比较阿卡波糖和二甲双胍降糖疗效研究

 卫生部中日友好医院杨文英教授介绍了中国新诊断2型糖尿病初始治疗方案探讨研究(MARCH)结果。   该研究为随机、前瞻性、多中心、开放、平行对照研究,将2型糖尿病患者随机分入阿卡波糖或二甲双胍组治疗24周,最终完成病例数为657例。结果显示,两类药物降低HbA1c水平相当。二甲双胍降低空腹血糖效果较好;在降低餐后2小时血糖方面,阿卡波糖优于二甲双胍。阿卡波糖减轻体重效果优于二甲双胍。接受两种药

二甲双胍抗肿瘤作用之辩

 二甲双胍抗肿瘤作用:证据颇多、机制渐明        中山大学附属第二医院李焱教授通过系统回顾流行病学资料、细胞与动物试验及临床研究结果,充分展示了二甲双胍抗肿瘤作用的证据。李教授还通过机制示意图结合简洁文字,清晰阐述了二甲双胍抑制肿瘤的潜在作用机制。    二甲双胍抗肿瘤作用:缺乏力证、有待探索